Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is an innovative company with a diverse product portfolio, strong international presence, and a focus on less invasive medical devices. The proposed update to society guidelines on transcatheter left atrial appendage occlusion is a positive development, highlighting the potential for growth in this area. Additionally, despite recent challenges, the company's management remains confident in its overall growth prospects and has a solid plan for recovering from the recent cybersecurity incident. Potential upside drivers include strong performance in electrophysiology and WATCHMAN, as well as potential growth from recent acquisitions and margin expansion.

Bears say

Boston Scientific is facing several challenges, such as slowing sales of its Watchman device due to mixed clinical evidence, share losses in the US EP market, and potential regulatory hurdles. The company has also faced economic uncertainties and pricing pressures in developed and emerging markets, which could impact its bottom line. Furthermore, the company's recent guidance cuts indicate a challenging near-term outlook, particularly for its Watchman and EP businesses.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.